Brokers Issue Forecasts for DBV Technologies S.A.’s Q3 2024 Earnings (NASDAQ:DBVT)

DBV Technologies S.A. (NASDAQ:DBVT) – HC Wainwright reduced their Q3 2024 EPS estimates for shares of DBV Technologies in a research note issued on Wednesday, July 31st. HC Wainwright analyst A. Fein now expects that the company will earn ($0.38) per share for the quarter, down from their prior estimate of ($0.30). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for DBV Technologies’ Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($1.43) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.59) EPS.

A number of other equities research analysts have also issued reports on the stock. JMP Securities lifted their target price on shares of DBV Technologies from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Wednesday, July 31st. StockNews.com began coverage on DBV Technologies in a research note on Friday, August 2nd. They issued a “hold” rating for the company.

DBV Technologies Trading Down 2.7 %

NASDAQ:DBVT opened at $0.90 on Monday. The business’s fifty day moving average price is $0.90 and its 200 day moving average price is $1.31. The firm has a market capitalization of $86.84 million, a price-to-earnings ratio of -1.07 and a beta of 0.68. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $3.70.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.42 million. During the same quarter in the prior year, the firm earned ($0.26) EPS.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.